Agios Pharm

Yahoo Finance • 22 hours ago

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:... Full story

Yahoo Finance • 8 days ago

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia Mitapivat is now approved for thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and... Full story

Yahoo Finance • 28 days ago

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)

Shares in Agios Pharmaceuticals(NASDAQ: AGIO) rose by 11.2% this week, putting the stock into positive territory for the year. The move comes after a well-received first-quarter earnings report that showed strong progress in Aqvesme's U.S.... Full story

Yahoo Finance • last month

BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is one of the 10 oversold small cap stocks to buy now. On April 21, BofA analyst Alec Stranahan reduced the price target on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to $41 from $44, while maintaini... Full story

Yahoo Finance • last month

Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)

Key Points Agios' price target was lowered due to increased regulatory risk. Novo Nordisk's etavopivat outperformed Agios' mitapivat in Phase 3 trials. Agios has a potential pipeline catalyst in 2026 with tebapivat.10 stocks we like bette... Full story

Yahoo Finance • last month

Agios (AGIO) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 31, 2025 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Brian M. GoffChief Financial Officer — Cecilia JonesChief Commercial Officer — Tsveta MilanovaChief Medical Officer —... Full story

Yahoo Finance • last month

Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock

Shares of Agios Pharmaceuticals took a header Monday after Novo Nordisk's rival sickle cell treatment succeeded in Phase 3 testing. Continue Reading... Full story

Yahoo Finance • last month

Agios Pharmaceuticals stock tumbles 25% after Novo data

Investing.com -- Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares fell 25% Monday after rival Novo Nordisk released positive data for its experimental sickle cell disease therapy. Novo Nordisk said etavopivat demonstrated a 27% reduction i... Full story

Yahoo Finance • 2 months ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Agios Pharmaceuticals, Inc. CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare di... Full story

Yahoo Finance • 2 months ago

Why Agios Pharmaceuticals Stock Is Up More Than 21% Today

Drugmaker Agios Pharmaceuticals(NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting. That's the overarching takeaway from this mornin... Full story

Yahoo Finance • 2 months ago

Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything

Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals(NASDAQ:AGIO), reported the open-market sale of 2,959 shares of common stock for a total of roughly $82,000 on March 5, 2026, according to an SE... Full story

Yahoo Finance • 3 months ago

How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The updated fair value estimate for Agios Pharmaceuticals has shifted to US$38.88 from US$36.75, while several bullish... Full story

Yahoo Finance • 4 months ago

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre-sNDA meeting with FDA f... Full story

Yahoo Finance • 5 months ago

UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday

With U.S. stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: UiPath Inc.(NYSE:PATH) shares gained in extended trading on Tuesday after it was announced tha... Full story

Yahoo Finance • 5 months ago

Here's Why Shares in Agios Pharmaceuticals Popped Today

Key Points The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappointing update earlier in the y... Full story

Yahoo Finance • 5 months ago

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) rem... Full story

Yahoo Finance • 6 months ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that... Full story

Yahoo Finance • 6 months ago

Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight

DelveInsight Business Research LLP The sickle cell disease market is anticipated to grow by 2034, driven by advances in disease mechanisms that have yielded new diagnostic and therapeutic approaches, opening the way to more drug developme... Full story

Yahoo Finance • 6 months ago

Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market Perform to Outperform with a $34 price tar... Full story

Yahoo Finance • 6 months ago

Stocks Settle Higher Before Nvidia Earnings

The S&P 500 Index ($SPX) (SPY) on Wednesday closed up by +0.38%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up by +0.56%.  December E-mini S&P futures (ESZ25) rose +0.39... Full story